| Bioactivity | Teprotumumab is an IGF-1 receptor (IGF-1R) blocking human monoclonal antibody. Teprotumumab binds to the ligand binding extracellular α-subunit domain of IGF-1R. Teprotumumab inhibits TSH and IGF-1 action in fibrocytes. Teprotumumab attenuates TSH-dependent IL-6 and IL-8 expression and Akt phosphorylation. Teprotumumab can be used for thyroid-associated ophthalmopathy research[1]. |
| Invitro | Teprotumumab (0-500 μg/mL, 12 h) attenuates the actions of both IGF-1 and TSH in fibrocytes. IGF-1R and TSHR mRNA abundance is unaffected by Teprotumumab after 24 hours[1]. |
| Name | Teprotumumab |
| CAS | 1036734-93-6 |
| Appearance | Liquid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Chen H, et al. Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes. J Clin Endocrinol Metab. 2014 Sep;99(9):E1635-40. |